Milner Institute announced as finalist for OBN Award
We are proud to announce that the Milner Therapeutics Institute has been shortlisted for a 2021 OBN Award in the category for Most Impactful Business Support Organisation. The OBN Awards, now in their 13th year, celebrate individuals and life sciences companies that...
Milner collaboration uncovers promising target for new drug development
Research in the Tzelepis lab, in collaboration with scientists from the Wellcome Sanger Institute and Harvard University, has identified a protein that plays a key role in transforming normal tissue to cancerous, as a possible target for drug development. The...
Milner group use combination of computational biology and machine learning to create comprehensive map of proteins involved in SARS-CoV-2 infection
Namshik Han’s group at the Milner Therapeutics Institute, have identified 200 approved drugs predicted to work against COVID-19 – of which only 40 are currently being tested in COVID-19 clinical trials. In a study published this week in Science Advances,...
Connect: Health Tech is launched
We are excited to announce that the University of Cambridge has launched the Connect: Health Tech microsite and online community platform, as part of the new University Enterprise Zone (UEZ) initiative. The delivery team behind Connect: Health Tech is the Milner...
Onco-Innovation collaborations awarded from pump prime call
Last month, the Onco-Innovation Programme — part of the CRUK Cambridge Centre and managed by our own Dr Rebecca Harris — launched a new rapid response data analysis pump prime call. This exciting new call was designed to seek collaborative project proposals from CRUK...
Milner collaboration targets RNA-modifying enzymes as promising anti-cancer strategy
Work at the Milner Therapeutics Institute by Director Tony Kouzarides and Kostas Tzelepis in collaboration with Storm Therapeutics has made a promising step towards developing a new drug for treating acute myeloid leukaemia. In a paper published today in Nature,...
Autophagy targets in neurodegeneration
We are excited to announce a new collaboration which has been set up through the Milner Therapeutics Consortium to investigate autophagy targets in neurodegeneration. This is the first such project to bring together multiple academic groups across the University and...
Milner Consortium reaches 10
We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the past month. Now with ten pharma partners and three academic partners, this has become one of the largest cross-sector...